Acadia Pharma (ACAD) Tops Q1 EPS by 5c, Misses on Revenue; Offers FY24 Guidance

Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of $0.10, $0.05 better than the analyst estimate of $0.05. Revenue for the quarter came in at $205.8 million versus the consensus estimate of $208.37 million.

Acadia is reiterating all of its 2024 guidance provided on February 27, 2024:

DAYBUE net product sales guidance in the range of $370 to $420 million.
NUPLAZID net product sales guidance in the range of $560 to $590 million.
R&D expense in the range of $305 to $325 million.
SG&A expense in the range of $455 to $480 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Increasing unusual option volume: UTHR ABUS OPRA GFL ACAD
• Indosat Tbk PT (ISAT:IJ) (PTITF) PT Raised to IDR35.10 at JPMorgan